The role of PARPi in patients with EGFR mutant NSCLC has been studied in a phase IB study of olaparib and the EGFR tyrosine kinase inhibitor (TKI) gefitinib (127). This evidence concerns the gene EGFR and non-small cell lung carcinoma.